CMS Adds Veltassa to CY16 Formulary Reference File; H.C. Wainwright Affirms Relypsa (RLYP) at 'Buy'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 5/26/2022
- Wall Street rallies as Fed minutes meet expectations
- NVIDIA Shares Drop 6% on Disappointing Guidance, While Q1 Earnings Beat
- Apple (AAPL) Reportedly Behind Schedule in Development of the New iPhone, Analyst Cuts Price Target on Risk to June Quarter iPhone Revenue
- Oil edges higher on tight supply, rising U.S. refining activity
- After-Hours Stock Movers 05/25: NVIDIA, Snowflake Sink on Weaker Guidance; Williams-Sonoma Surges on Strong Numbers (more...)
- Wells Fargo (WFC) has fired dozens of loan officers accused of misusing appraisal waivers. Some say the bank gave them mixed signals - Business Insider
- Apple (AAPL) Reportedly Behind Schedule in Development of the New iPhone, Analyst Cuts Price Target on Risk to June Quarter iPhone Revenue
- Wall Street rallies as Fed minutes meet expectations
- Michael Burry Posts Cryptic Tweet Raising Spector of 2008 Crash - Bloomberg
- NVIDIA (NVDA) Tops Q1 EPS by 7c, Q2 Revenue Guidance Misses
- After-Hours Stock Movers 05/25: NVIDIA, Snowflake Sink on Weaker Guidance; Williams-Sonoma Surges on Strong Numbers (more...)
- Pre-Open Stock Movers 05/25: Retailers Express, Nordstrom Gain Following Earnings; Verrica Pharma Sinks on FDA CRL (more...)
- Companies with NDRs 5/25
- After-Hours Stock Movers 05/24: Wendy's Gains on Possible Peltz Deal, Nordstrom Up Following Earnings (more...)
- Pre-Open Stock Movers 05/24: Snap's Warning Sends Tech Stocks Reeling; Insulet Gains on Deal Talk (more...)
Relypsa (RLYP) Veltassa 'Off To A Strong Start' - Spherix Global Insights
February 11, 2016 11:33 AM ESTSpherix Global Insights said a recent study with 101 US nephrologists in late January 2016 showed "promising activity" for Relypsa's (NASDAQ: RLYP) Veltassa.
Prior to launch, but following the October approval, unaided awareness of Veltassa was high which likely paved the way for early trial. In addition to the 20% of surveyed nephrologists... More
